ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, Sandro Pignata, Isabelle Ray‐Coquard et al.|Annals of Oncology|2019Cited by 1.2k
Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinomaD Katsaros, C. Bumma, Irene A. Rigault de la Longrais et al.|Annals of Oncology|2005Cited by 25
Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences.Luigi Cattel, Annamaria Ferrero, Roberto Passera et al.|PubMed|2006Cited by 8
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implicationsAnna Surbone, Paolo Zola, Luca Fuso et al.|BMC Research Notes|2012Cited by 3